Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Research analysts at Zacks Research increased their Q2 2025 EPS estimates for Surmodics in a research note issued to investors on Monday, November 25th. Zacks Research analyst D. Dey now forecasts that the company will earn ($0.08) per share for the quarter, up from their previous estimate of ($0.12). The consensus estimate for Surmodics' current full-year earnings is $0.17 per share. Zacks Research also issued estimates for Surmodics' Q1 2026 earnings at $0.22 EPS.
Other research analysts also recently issued reports about the stock. Needham & Company LLC restated a "hold" rating on shares of Surmodics in a research report on Thursday, November 7th. StockNews.com began coverage on shares of Surmodics in a report on Saturday, November 23rd. They set a "hold" rating for the company. Five research analysts have rated the stock with a hold rating, According to data from MarketBeat, Surmodics has an average rating of "Hold" and an average target price of $50.00.
Get Our Latest Analysis on Surmodics
Surmodics Stock Down 0.1 %
NASDAQ SRDX traded down $0.04 on Thursday, hitting $39.54. 120,025 shares of the stock traded hands, compared to its average volume of 228,987. The stock has a 50-day moving average of $38.51 and a 200 day moving average of $39.58. Surmodics has a twelve month low of $25.17 and a twelve month high of $42.44. The company has a market capitalization of $566.45 million, a P/E ratio of -48.81 and a beta of 1.20. The company has a current ratio of 3.96, a quick ratio of 3.22 and a debt-to-equity ratio of 0.25.
Surmodics (NASDAQ:SRDX - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.14. Surmodics had a negative net margin of 9.15% and a negative return on equity of 3.79%. The company had revenue of $33.23 million during the quarter, compared to analyst estimates of $30.69 million.
Insider Transactions at Surmodics
In other Surmodics news, CFO Timothy J. Arens sold 7,009 shares of the company's stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $39.44, for a total value of $276,434.96. Following the transaction, the chief financial officer now owns 70,350 shares of the company's stock, valued at approximately $2,774,604. This represents a 9.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 8.90% of the company's stock.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Lazard Asset Management LLC grew its position in Surmodics by 13.4% during the 1st quarter. Lazard Asset Management LLC now owns 5,679 shares of the company's stock worth $166,000 after purchasing an additional 673 shares in the last quarter. Quest Partners LLC boosted its position in Surmodics by 107,100.0% during the 3rd quarter. Quest Partners LLC now owns 1,072 shares of the company's stock worth $42,000 after acquiring an additional 1,071 shares during the period. Los Angeles Capital Management LLC grew its stake in Surmodics by 3.5% during the 2nd quarter. Los Angeles Capital Management LLC now owns 36,425 shares of the company's stock valued at $1,531,000 after acquiring an additional 1,221 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Surmodics by 1.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 116,311 shares of the company's stock valued at $4,511,000 after acquiring an additional 1,491 shares in the last quarter. Finally, Longfellow Investment Management Co. LLC acquired a new position in shares of Surmodics in the 3rd quarter valued at about $67,000. 96.63% of the stock is currently owned by institutional investors and hedge funds.
Surmodics Company Profile
(
Get Free Report)
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
Featured Stories
Before you consider Surmodics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surmodics wasn't on the list.
While Surmodics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
